News and Trends 17 Jan 2023 Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity Multus Biotechnology Limited, a U.K.-based start-up creating ingredients for the affordable scale-up of cellular agriculture, has completed a £7.9 million ($9.5 million) funding round led by Mandi Ventures. Other investors include SOSV, Big Idea Ventures and SynBioVen, alongside Asahi Kasei, a global company that contributes to a sustainable society by tackling evolving challenges in materials, […] January 17, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 ExeVir Bio secures funding for COVID program ExeVir Bio, a Belgian biotech company developing nanobody therapies for broad protection against infectious diseases, has secured a venture debt financing agreement of up to €25 million ($26.5 million) with the European Investment Bank (EIB). The EIB financing will help advance ExeVir Bio’s lead asset, XVR012, into clinical trials for COVID-19. ExeVir Bio’s COVID-19 development […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 ErVaccine raises €4.5M to start therapeutic cancer vaccine trial ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de l’Innovation (ADI) program. ErVaccine is a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, France, which develops next-generation […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2023 Actimed Therapeutics raises £10M for cancer cachexia treatment Actimed Therapeutics Ltd has completed its second and final £5 million ($6 million) tranche of seed financing. The round was closed with an investment by Indian pharmaceutical company, Mankind Pharma, marking Mankind’s first overseas investment of this type. Actimed Therapeutics is a U.K. based clinical stage specialty pharmaceutical company focused on bringing innovation to the […] January 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Affibody signs €20 million loan agreement Affibody Medical AB has received a €20 million ($21.2 million) venture debt loan facility from the European Investment Bank, EIB, backed by the InvestEU program. The investment will support Affibody’s research and development activities in Europe of the next-generation biopharmaceuticals targeting unmet medical needs in the immunology and oncology fields. “We are very pleased and […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Ganymede Bio raises $12.75M for data platform Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, has announced a $12.75 million series A funding round, led by Caffeinated Capital. This follows a $2.9 million seed round completed earlier this year, bringing the total to more than $15.6 million. Founded in 2022, Ganymede Bio has exceeded $1 million […] December 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Biomica raises $20M to advance microbiome-based therapeutics pipeline Biomica Ltd., a subsidiary of Evogene Ltd., has signed a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities. The financing round will enable Biomica to develop its pipeline of microbiome-based therapeutics. The company […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Anocca secures €25M to develop next-generation T-cell therapies for cancer Anocca, a fully integrated cell therapy biotechnology company, has secured €25 million ($26.5 million) venture debt financing from the European Investment Bank (EIB). Anocca’s CEO and co-founder Reagan Jarvis said: “We’re delighted that the EIB has chosen to support us as we build a critical piece of advanced biotechnology capability and infrastructure in Sweden. Anocca’s […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 iOnctura raises €17.5M for pancreatic cancer therapy iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022 LIfT BioSciences gets a double boost LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […] December 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease Alchemab Therapeutics has been awarded a grant of £1.7 million ($2 million) from Innovate UK’s Biomedical Catalyst (BMC) 2022 funding competition to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first […] December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 MinervaX raises €72M to develop Group B Streptococcus vaccine MinervaX ApS, a privately held Danish biotech company developing a novel vaccine against Group B Streptococcus (GBS), has completed a €72 million ($76.5 million) financing round. The equity financing of €22 million ($23.4 million) was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone […] December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email